XRCC3 and RAD51 expression are associated with clinical factors in breast cancer.
Where this comes from
- Record sourced from PubMed, PMID 23977219.
- Also identified by DOI 10.1371/journal.pone.0072104 and PMC identifier 3748017.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
AIMS: XRCC3 and RAD51 are two important members in homologous recombination repair pathway. This study was performed to detect the expressions of these two molecules in breast cancer and explore their correlations with clinicopathological factors. METHODS AND RESULTS: Immunohistochemistry was used to detect protein expressions of XRCC3 and RAD51 in 248 cases of breast cancer tissue and 78 cases of adjacent non-cancerous tissue. Data showed that expressions for both XRCC3 and RAD51 were significantly increased in breast cancer. High XRCC3 expression was associated with large tumor size and positive PR and HER2 status, while high RAD51 expression was associated with axillary lymph node metastasis and positive PR and HER2 status. The result of multivariate analysis demonstrated that HER2, PR and RAD51 were significantly association with XRCC3. And besides XRCC3, axillary lymph node metastasis and PR were significantly correlated with RAD51. CONCLUSIONS: XRCC3 and RAD51 were significantly associated with clinicopathological factors and they might play important roles in the development and progress of breast cancer.
Medical subject headings
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- DNA-Binding Proteins
- Rad51 Recombinase